Sydney, June 13, 2026, 02:14 AEST
- CSL ended at A$107.51 Friday, up 0.26%. The stock stretched its rebound to six sessions after a bigger move on Thursday.
- S&P/ASX 200 climbed 1.98% to 8,804 on Friday. CSL is still under the spotlight as the market questions if its rebound after the earnings downgrades will stick.
CSL Limited shares ended Friday at A$107.51, up 28 cents, or 0.26%. That’s off delayed market data. The stock’s move was modest and trailed the 1.98% jump for the Australian market. CSL’s market cap hovered near A$52.18 billion. The stock has drawn extra focus as one of the ASX’s key turnaround names following its sharp de-rating this year.
CSL surged 4.16% to A$107.23 on Thursday, hitting an intraday high of A$108.46. The Bull called CSL one of the ASX 200’s late-session standouts. The move came after a run of selling that had weighed on the stock. While shares often climb when the outlook for earnings improves, risk premiums fall, or bargain hunters return, this bounce looked like more of a relief rally than a shift in CSL’s fundamentals.
CSL hasn’t posted any new operating announcements to its ASX page since June 9, when it notified a cessation of securities. Another healthcare report said CSL Behring, the company’s plasma unit, signed a five-year lease to test Clever Culture Systems’ APAS Independence system at the Broadmeadows site. That news seems more material for Clever Culture than for CSL’s short-term earnings.
CSL’s May 11 update still hangs over the stock. The company cut its FY26 constant-currency forecast to around US$15.2 billion in revenue, with NPATA — net profit after tax before amortisation and major one-offs — seen at about US$3.1 billion. Constant currency removes FX moves. Interim CEO Gordon Naylor said, “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.”
The downgrade explains the sharp drop before shares bounced. CSL said U.S. immunoglobulin sales will take about a US$300 million hit from channel inventory shifts, with China albumin down roughly US$200 million on softer prices. Other impacts add up to about US$150 million, including the Middle East conflict, HEMGENIX gains and iron competition. CSL is also flagging around US$5 billion in extra non-cash, pre-tax impairments for FY26 and FY27, after booking US$1.5 billion at the half. Impairments cut asset value on paper and don’t mean cash is going out, but they can point to weaker returns from earlier spending.
Analysts are still divided, leaving the share price unsteady. According to Investing.com’s analyst table, there are 7 buy ratings and 9 hold ratings, no sells. The mean 12-month price target sits at A$140.39. But calls differ: UBS reiterated a buy with a A$158 price target as of June 10, while Jefferies cut its rating late May and kept a A$108 target. Friday’s close at A$107.51 is right around Jefferies’ more cautious forecast, and sits well below the average target.
CSL’s bulls argue the company still has major plasma, vaccine and specialty-medicine businesses, with Reuters listing its main units as CSL Behring, CSL Seqirus and CSL Vifor. CSL says it is seeing mid- to high-single-digit U.S. immunoglobulin demand growth from end customers. Bears point to a string of downgrades, impairments tied to Vifor, weak China albumin prices, iron drug competition and the ongoing CEO transition as reasons the stock no longer commands its old premium.
CSL’s next big event is its full-year results and dividend on August 18. The financial year wraps up June 30. To move the stock from simply looking cheap after the recent drop to looking attractive, investors say they want to see CSL Behring’s second-half revenue growth, some sign that impairment risk is limited, and management starting to rebuild confidence for FY27 earnings. Right now, CSL trades as a high-risk turnaround play at this price—maybe interesting for buyers who think plasma can bounce back, but still not a clear bargain while issues around guidance, Vifor returns and succession sit unresolved.
